title: Effects of diproteverine, a new calcium antagonist on sinoatrial node and atrioventricular conduction in conscious unsedated dogs.
abstract: The electrophysiologic effects of diproteverine were studied in the conscious nonsedated chronically instrumented dog. Diproteverine at 0.25-0.75 mg/kg (i.e., at plasma levels within the assumed therapeutic range) dose-relatedly decreases heart rate, increases corrected sinus node recovery time, and decreases Wenckebach point. These effects are observed at plasma levels ranging between 16.2 +/- 4.1 and 144.7 +/- 12.5 ng/ml. After cholinergic blockade with N-methylscopolammonium, diproteverine lowers heart rate (greater than or equal to 0.25 mg/kg), increases corrected sinus node recovery time, and decreases Wenckebach point (greater than or equal to 0.5 mg/kg). After propranolol, diproteverine only significantly reduces corrected sinus node recovery time 5 min after the third administration (0.75 mg/kg). After pharmacologic autonomic blockade by N-methylscopolammonium propranolol combination, diproteverine lowers intrinsic heart rate (greater than or equal to 0.25 mg/kg) and Wenckebach point (greater than or equal to 0.5 mg/kg). Diproteverine does not modify mean blood pressure. These results show that diproteverine administered with and without pharmacologic autonomic blockade in the conscious dog causes dose-related depressant effects on sinus node function and atrioventricular conduction without producing significant vasodilatation.
authors: Laboratoire de Pharmacologie Médicale, INSERM U195, Faculté de Médecine, Clermont-Ferrand, France.
authors: J P
authors: JP
authors: Kantelip
authors: J M
authors: JM
authors: Talmant
authors: P
authors: P
authors: Duchene-Marullaz
mesh_terms: D000818:Animals; D001283:Atrioventricular Node / Q000187:drug effects*; D001337:Autonomic Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D011950:Receptors, Cholinergic / Q000187:drug effects; D011976:Receptors, Muscarinic / Q000187:drug effects; D012849:Sinoatrial Node / Q000187:drug effects*
chemical_list: D001337:Autonomic Agents; D002121:Calcium Channel Blockers; D007546:Isoquinolines; D011950:Receptors, Cholinergic; D011976:Receptors, Muscarinic; C049847:diproteverine